Wednesday, July 8, 2026

Patent intelligence · US

US 11060144

Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype

granted A61KA61K31/16A61PA61P25/00
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 15
Applicant portfolio 96
Patent details — US 11060144
Jurisdiction
US
Status
granted
Grant date
Jul 13, 2021
Expiration
Jul 8, 2041
Claims
6
CPC classes
A61K, A61K31/16, A61P, A61P25/00
View on Google Patents ↗

Quick answer

US 11060144 (Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype) is held by VANDA PHARMACEUTICALS INC.. Status: granted. Granted Jul 13, 2021. Expires Jul 8, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
6
CPC classes
A61K, A61K31/16, A61P, A61P25/00, A61P25/20, A61P43/00

More from VANDA PHARMACEUTICALS INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12427132

    Method of improving sleep

    VANDA PHARMACEUTICALS INC. · Expires Sep 25, 2045

    granted
  2. US 12419869

    Methods of treating multiple sclerosis

    VANDA PHARMACEUTICALS INC. · Expires Sep 18, 2045

    granted
  3. US 12409167

    Pharmaceutical combination comprising a selective S1P1 receptor agonist

    VANDA PHARMACEUTICALS INC. · Expires Sep 4, 2045

    granted
  4. US 12403134

    Method for improving or enhancing cognition

    VANDA PHARMACEUTICALS INC. · Expires Aug 28, 2045

    granted
  5. US 12357616

    Methods of treating multiple sclerosis

    VANDA PHARMACEUTICALS INC. · Expires Jul 10, 2045

    granted
  6. US 12336980

    Dosing regimen for a selective S1P1 receptor agonist

    VANDA PHARMACEUTICALS INC. · Expires Jun 19, 2045

    granted
  7. US 12318375

    Method of treatment with tradipitant

    VANDA PHARMACEUTICALS INC. · Expires May 29, 2045

    granted
  8. US 12201604

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Expires Jan 16, 2045

    granted

Frequently asked questions

What is US patent 11060144?

US 11060144 (Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype) is held by VANDA PHARMACEUTICALS INC.. Status: granted. Granted Jul 13, 2021. Expires Jul 8, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11060144?

VANDA PHARMACEUTICALS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 96 pharmaceutical patents for this assignee.

When does US 11060144 expire?

Our index shows an expiration date of Jul 8, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.